NCT06650501View on ClinicalTrials.gov

Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 7, 2026

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions
Staphylococcus Aureus EndocarditisStaphylococcus Aureus SepticemiaStaphylococcus Aureus BacteremiaStaphylococcus Aureus Bloodstream InfectionS. Aureus BacteremiaS. Aureus Bloodstream Infection
Interventions
DRUG

Dabigatran

Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.

DRUG

Apixaban

Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

DRUG

edoxaban

Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

DRUG

Rivaroxaban

Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

Trial Locations (1)

H4A3S1

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal

All Listed Sponsors
collaborator

University of Melbourne

OTHER

lead

Emily McDonald

OTHER